Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its operations are carried out through the following business divisions: Pharmaceuticals and Medical Devices, Agrochemicals and Animal Health Products, Overseas Activity, Research & Development, and Licensing Opportunities. The Pharmaceuticals and Medical Devices division offers artz(anti-osteoarthritis), clenafin (topical onychomycosis treatment product), seprafilm (anti-adhesive absorbent barrier), lipidil (anti-hyperlipidemia product), fiblast spray (wound-healing product), mentax (anti-trichophyton product) and generic drugs. The Agrochemicals and Animal Health Products division provides polyoxins (fungicides), pentoxazone (rice herbicide), salinomycin (anti-coccidial for chickens) and colistin sulfate (polypeptide antibiotic). The Overseas Activity division engages in the business of license and distributorship agreements regarding original products. The Research & Development division engages in the drug discovery research focuses on such areas of strength as inflammation, immunity, allergies and pain relief in addition to its core competence of fungal infection disease. The Licensing Opportunities division engages in the R&D collaboration and marketing alliance in the therapeutic areas such as orthopedics, dermatology, mycology, peri-surgical and others. It also engages in the management of real estate properties of the group. The company was founded in March 1917 and is headquartered in Tokyo, Japan.
Primary Stock Exchange Listings